

## Alfasigma: production plant in Alanno (Pescara)

Today Alfasigma has four production sites in Italy: Alanno in Abruzzo, Pomezia and Sermoneta in Lazio, Trezzano Rosa In Lombardia. Sermoneta is a chemical plant, while the facilities at Alanno, Pomezia and Trezzano produce prescription and over-the-counter drugs.

The Alanno plant, near Pescara, employs 400 people dedicated to production and related services, more than a third of whom hold university degrees and half of whom are women.



**History** — The Alanno plant was founded in 1984 and is a hub of excellence in the area.

**Dimensions** — To rationalise the space and maximise efficiency by streamlining the workflows, the facility is divided into 11 departments housed in 7 buildings.

- 128,500 m<sup>2</sup> total surface;
- 8,900 m<sup>2</sup> covered area for production and laboratories (43%);
- 7,600 m<sup>2</sup> logistics centre (37%);
- 4,000 m<sup>2</sup> for services and utilities (20%).

**Production capacity** — The site production capacity is:

- 55-60 million packs;
- 600 million tablets/capsules
- 85 million injectable doses (liquids and lyophilisates)
- 40% of the production is for export, including EU, Japan and USA

**Products and pharmaceutical forms** — The Alanno plant processes rifaximin, a molecule for the treatment of gastrointestinal disorders, which holds the record for US sales of an Italian-owned drug (over 1.5 billion euros; source: IQVIA). The other drug that has been exported with great success in recent years (double-digit growth in 2019; source: IQVIA) is sulodexide, indicated for chronic venous ulcers and vascular diseases with the risk of thrombosis.

In addition to rifaximin and sulodexide, parnaparin, phosphocreatine, diclofenac and the NeoBorocillin family are produced in Alanno.

**News and future developments** — This high-tech pharmaceutical plant saw further expansion between 2018 and 2021, with the addition of two new sterile departments, one to increase the production of pre-filled syringes and vials by more than 40 million units per year, the other specifically designed for the production of sterile powders, with high-performance bottle filling equipment. The investment for this upgrading was 20 million euros.

**Giuseppe Allocca** is the Corporate Operations & Supply Chain Executive Director. With a degree in Chemistry, he joined Alfasigma in January 2020 after a long experience in Pfizer where he managed manufacturing plants in Italy and abroad.

**Media Relations**

[CorporateCommunication@alfasigma.com](mailto:CorporateCommunication@alfasigma.com)

[www.alfasigma.com](http://www.alfasigma.com)

*Last update, November 2022.*